BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

100 related articles for article (PubMed ID: 21258419)

  • 1. Clonally identical Hodgkin's disease develops after allogeneic hematopoietic cell transplant for CLL.
    Tseng D; Jones CD; Anderson M; Warnke R; Zehnder JL; Miklos DB
    Bone Marrow Transplant; 2011 Dec; 46(12):1576-8. PubMed ID: 21258419
    [No Abstract]   [Full Text] [Related]  

  • 2. Hodgkin's lymphoma relapsing after autologous transplantation: allogeneic hematopoietic stem cell transplantation using a strategy of reduced intensity conditioning, and T-cell depletion with T-cell add-back.
    Verholen F; Terrettaz M; Roosnek E; Passweg JR; Chalandon Y
    Eur J Haematol; 2009 Sep; 83(3):273-5. PubMed ID: 19500136
    [No Abstract]   [Full Text] [Related]  

  • 3. First case of ovarian Sertoli-Leydig cell tumor after an allogeneic hematopoietic stem cell transplantation for Hodgkin's disease.
    Perrone S; Pecorella I; Barberi W; Valle V; Torelli GF; Natalino F; Mercanti C; Foà R; Iori AP
    Leuk Res; 2012 Aug; 36(8):e185-6. PubMed ID: 22633001
    [No Abstract]   [Full Text] [Related]  

  • 4. Allogeneic stem cell transplantation for the non-Hodgkin's lymphomas and Hodgkin's disease.
    Hale GA; Phillips GL
    Cancer Treat Rev; 2000 Dec; 26(6):411-27. PubMed ID: 11139372
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Allogeneic transplantation in malignant lymphoma].
    Stötzer OJ; Schleuning M; Ledderose G; Hiddemann W; Kolb HJ
    Dtsch Med Wochenschr; 2001 Sep; 126(39):1062-9. PubMed ID: 11602913
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Autologous and allogeneic stem cell transplantation in Hodgkin's lymphoma.
    Sureda A
    Hematol Oncol Clin North Am; 2007 Oct; 21(5):943-60. PubMed ID: 17908630
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Allogeneic haematopoietic stem-cell transplantation with reduced intensity conditioning for advanced stage Hodgkin's lymphoma in Sweden: high incidence of post transplant lymphoproliferative disorder.
    Johansson JE; Remberger M; Lazarevic VLj; Hallböök H; Wahlin A; Kimby E; Juliusson G; Omar H; Hägglund H
    Bone Marrow Transplant; 2011 Jun; 46(6):870-5. PubMed ID: 20956959
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [High-dose chemotherapy and autologous stem cell transplantation for refractory and relapsing Hodgkin's disease as first-line therapy-- studies at Sheba Medical Center--Tel Hashomer].
    Avigdor A; Hardan I; Shpilberg O; Raanani P; Grotto I; Ben-Bassat I
    Harefuah; 2000 Sep; 139(5-6):174-9, 248, 247. PubMed ID: 11062945
    [TBL] [Abstract][Full Text] [Related]  

  • 9. An EBMT registry matched study of allogeneic stem cell transplants for lymphoma: allogeneic transplantation is associated with a lower relapse rate but a higher procedure-related mortality rate than autologous transplantation.
    Peniket AJ; Ruiz de Elvira MC; Taghipour G; Cordonnier C; Gluckman E; de Witte T; Santini G; Blaise D; Greinix H; Ferrant A; Cornelissen J; Schmitz N; Goldstone AH;
    Bone Marrow Transplant; 2003 Apr; 31(8):667-78. PubMed ID: 12692607
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Reduced-intensity allogeneic transplantation in patients with refractory or progressive Hodgkin's disease after high-dose chemotherapy and autologous stem cell infusion.
    Todisco E; Castagna L; Sarina B; Mazza R; Anastasia A; Balzarotti M; Banna G; Tirelli U; Soligo D; Santoro A
    Eur J Haematol; 2007 Apr; 78(4):322-9. PubMed ID: 17253967
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Autotransplants for Hodgkin's disease in first relapse or second remission: a report from the autologous blood and marrow transplant registry (ABMTR).
    Lazarus HM; Loberiza FR; Zhang MJ; Armitage JO; Ballen KK; Bashey A; Bolwell BJ; Burns LJ; Freytes CO; Gale RP; Gibson J; Herzig RH; LeMaistre CF; Marks D; Mason J; Miller AM; Milone GA; Pavlovsky S; Reece DE; Rizzo JD; van Besien K; Vose JM; Horowitz MM
    Bone Marrow Transplant; 2001 Feb; 27(4):387-96. PubMed ID: 11313668
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prognostic factors for survival after high-dose therapy and autologous stem cell transplantation for patients with relapsing Hodgkin's disease: analysis of 280 patients from the French registry. Société Française de Greffe de Moëlle.
    Brice P; Bouabdallah R; Moreau P; Divine M; André M; Aoudjane M; Fleury J; Anglaret B; Baruchel A; Sensebe L; Colombat P
    Bone Marrow Transplant; 1997 Jul; 20(1):21-6. PubMed ID: 9232251
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A prognostic model for prolonged event-free survival after autologous or allogeneic blood or marrow transplantation for relapsed and refractory Hodgkin's disease.
    Tey S; Butler J; Durrant S; Hill G; Morton J; Kennedy G
    Bone Marrow Transplant; 2005 Sep; 36(6):553-4; author reply 554. PubMed ID: 16044146
    [No Abstract]   [Full Text] [Related]  

  • 14. Long-term results of autologous stem cell transplantation for Hodgkin's disease (HD) and low-/intermediate-grade B non-Hodgkin's lymphoma (NHL): a report from the Austrian Stem Cell Transplantation Registry (ASCTR).
    Nachbaur D; Greinix HT; Koller E; Krieger O; Linkesch W; Kasparu H; Pober M; Hinterberger W; Hausmaninger H; Heistinger M; Ulsperger E; Karlhuber S; Schwinger W; Lindner B
    Ann Hematol; 2005 Jul; 84(7):462-73. PubMed ID: 15726362
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Second autologous stem cell transplant for multiply relapsed Hodgkin's disease.
    Lin TS; Avalos BR; Penza SL; Marcucci G; Elder PJ; Copelan EA
    Bone Marrow Transplant; 2002 May; 29(9):763-7. PubMed ID: 12040474
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Successful allogeneic stem cell transplantation with nonmyeloablative conditioning in patients with relapsed Hodgkin's disease following autologous stem cell transplantation.
    Ruiz-Argüelles GJ; López-Martínez B; López-Ariza B
    Arch Med Res; 2003; 34(3):242-5. PubMed ID: 14567405
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Crohn's disease complicated by relapsed extranodal Hodgkin's lymphoma: prolonged complete remission after unmanipulated PBPC autotransplant.
    Musso M; Porretto F; Crescimanno A; Bondì F; Polizzi V; Scalone R
    Bone Marrow Transplant; 2000 Oct; 26(8):921-3. PubMed ID: 11081397
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Periodic morphologic, cytogenetic and clonality evaluation after autologous peripheral blood progenitor cell transplantation in patients with lymphoproliferative malignancies.
    Laurenti L; Chiusolo P; Garzia MG; Zini G; Sorà F; Piccirillo N; Piccioni P; Zollino M; Leone G; Sica S
    Haematologica; 2002 Jan; 87(1):59-66. PubMed ID: 11801466
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Reduced-intensity allogeneic stem cell transplantation in relapsed and refractory Hodgkin's disease: low transplant-related mortality and impact of intensity of conditioning regimen.
    Anderlini P; Saliba R; Acholonu S; Okoroji GJ; Donato M; Giralt S; Andersson B; Ueno NT; Khouri I; De Lima M; Hosing C; Cohen A; Ippoliti C; Romaguera J; Rodriguez MA; Pro B; Fayad L; Goy A; Younes A; Champlin RE
    Bone Marrow Transplant; 2005 May; 35(10):943-51. PubMed ID: 15806128
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prognostic factors for disease progression after high-dose chemotherapy and autologous hematopoietic stem cell transplantation for recurrent or refractory Hodgkin's lymphoma.
    Popat U; Hosing C; Saliba RM; Anderlini P; van Besien K; Przepiorka D; Khouri IF; Gajewski J; Claxton D; Giralt S; Rodriguez M; Romaguera J; Hagemeister F; Ha C; Cox J; Cabanillas F; Andersson BS; Champlin RE
    Bone Marrow Transplant; 2004 May; 33(10):1015-23. PubMed ID: 15048145
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.